Reilly JT. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. „Hematology”. 14 (1), s. 1–10, luty 2009. DOI: 10.1179/102453309X385115. PMID: 19154658.
Petrides PE. Anagrelide: what was new in 2004 and 2005?. „Seminars in Thrombosis and Hemostasis”. 32 (4 Pt 2), s. 399–408, czerwiec 2006. DOI: 10.1055/s-2006-942760. PMID: 16810615.
Dingli D., Tefferi A. Anagrelide: an update on its mechanisms of action and therapeutic potential. „Expert Review of Anticancer Therapy”. 4 (4), s. 533–41, sierpień 2004. DOI: 10.1586/14737140.4.4.533. PMID: 15270658.
Thiele J., Kvasnicka HM., Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production.. „Seminars in Thrombosis and Hemostasis”. 32 (4 Pt 2), s. 352–61, czerwiec 2006. DOI: 10.1055/s-2006-942756. PMID: 16810611.
Cacciola RR., Di Francesco E., Pezzella F., Tibullo D., Giustolisi R., Cacciola E. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. „Acta Haematologica”. 118 (4), s. 215–8, 2007. DOI: 10.1159/000111776. PMID: 18057866.
Wang G., Franklin R., Hong Y., Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. „British Journal of Pharmacology”. 146 (3), s. 324–32, październik 2005. DOI: 10.1038/sj.bjp.0706341. PMID: 16041400.
Birgegård G. Long-term management of thrombocytosis in essential thrombocythaemia. „Annals of Hematology”. 88 (1), s. 1–10, styczeń 2009. DOI: 10.1007/s00277-008-0531-7. PMID: 18629498.
Harrison CN., Campbell PJ., Buck G., Wheatley K., East CL., Bareford D., Wilkins BS., van der Walt JD., Reilly JT., Grigg AP., Revell P., Woodcock BE., Green AR. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. „The New England Journal of Medicine”. 353 (1), s. 33–45, lipiec 2005. DOI: 10.1056/NEJMoa043800. PMID: 16000354.
Doubek M., Brychtova Y., Doubek R., Janku P., Mayer J. Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. „Annals of Hematology”. 83 (11), s. 726–7, listopad 2004. DOI: 10.1007/s00277-004-0904-5. PMID: 15278298.
Dame C., Sutor AH. Primary and secondary thrombocytosis in childhood. „British Journal of Haematology”. 129 (2), s. 165–77, kwiecień 2005. DOI: 10.1111/j.1365-2141.2004.05329.x. PMID: 15813844.
Raghavan M., Mazer MA., Brink DJ. Severe hypersensitivity pneumonitis associated with anagrelide. „The Annals of Pharmacotherapy”. 37 (9), s. 1228–31, wrzesień 2003. DOI: 10.1345/aph.1D071. PMID: 12921504.
Spencer EM., Lawrence DS. 'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide. „Clinical and Laboratory Haematology”. 28 (1), s. 63–5, luty 2006. DOI: 10.1111/j.1365-2257.2006.00740.x. PMID: 16430463.
Rappoport L., Körber A., Grabbe S., Dissemond J. Appearance of leg ulcers associated with intake of anagrelide. „Deutsche Medizinische Wochenschrift”. 132 (7), s. 319–21, luty 2007. DOI: 10.1055/s-2007-959325. PMID: 17286219.
Petrides PE., Gisslinger H., Steurer M., Linkesch W., Krumpl G., Schüller A., Widmann R. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. „Clinical Therapeutics”. 31 (2), s. 386–98, luty 2009. DOI: 10.1016/j.clinthera.2009.02.008. PMID: 19302911.
Reilly JT. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. „Hematology”. 14 (1), s. 1–10, luty 2009. DOI: 10.1179/102453309X385115. PMID: 19154658.
Voglová J., Maisnar V., Beránek M., Chrobák L. Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase. „Vnitřní Lékařství”. 52 (9), s. 819–22, wrzesień 2006. PMID: 17091608.
Storen EC., Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia.. „Blood”. 97 (4), s. 863–6, luty 2001. PMID: 11159509.
Petrides PE. Anagrelide: what was new in 2004 and 2005?. „Seminars in Thrombosis and Hemostasis”. 32 (4 Pt 2), s. 399–408, czerwiec 2006. DOI: 10.1055/s-2006-942760. PMID: 16810615.
Mazur EM., Rosmarin AG., Sohl PA., Newton JL., Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. „Blood”. 79 (8), s. 1931–7, kwiecień 1992. PMID: 1562721.
Dingli D., Tefferi A. Anagrelide: an update on its mechanisms of action and therapeutic potential. „Expert Review of Anticancer Therapy”. 4 (4), s. 533–41, sierpień 2004. DOI: 10.1586/14737140.4.4.533. PMID: 15270658.
Thiele J., Kvasnicka HM., Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production.. „Seminars in Thrombosis and Hemostasis”. 32 (4 Pt 2), s. 352–61, czerwiec 2006. DOI: 10.1055/s-2006-942756. PMID: 16810611.
Cacciola RR., Di Francesco E., Pezzella F., Tibullo D., Giustolisi R., Cacciola E. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. „Acta Haematologica”. 118 (4), s. 215–8, 2007. DOI: 10.1159/000111776. PMID: 18057866.
Wang G., Franklin R., Hong Y., Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. „British Journal of Pharmacology”. 146 (3), s. 324–32, październik 2005. DOI: 10.1038/sj.bjp.0706341. PMID: 16041400.
Jones GH., Venuti MC., Alvarez R., Bruno JJ., Berks AH., Prince A. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. „Journal of Medicinal Chemistry”. 30 (2), s. 295–303, luty 1987. PMID: 3027338.
Venuti MC., Stephenson RA., Alvarez R., Bruno JJ., Strosberg AM. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline. „Journal of Medicinal Chemistry”. 31 (11), s. 2136–45, listopad 1988. PMID: 2846839.
Birgegård G. Long-term management of thrombocytosis in essential thrombocythaemia. „Annals of Hematology”. 88 (1), s. 1–10, styczeń 2009. DOI: 10.1007/s00277-008-0531-7. PMID: 18629498.
Mazzucconi MG., Redi R., Bernasconi S., Bizzoni L., Dragoni F., Latagliata R., Santoro C., Mandelli F. A long-term study of young patients with essential thrombocythemia treated with anagrelide. „Haematologica”. 89 (11), s. 1306–13, listopad 2004. PMID: 15531452.
Erusalimsky JD., Hong Y., Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?. „Experimental Hematology”. 30 (7), s. 625–6; author reply 626–7, lipiec 2002. PMID: 12135656.
Harrison CN., Campbell PJ., Buck G., Wheatley K., East CL., Bareford D., Wilkins BS., van der Walt JD., Reilly JT., Grigg AP., Revell P., Woodcock BE., Green AR. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. „The New England Journal of Medicine”. 353 (1), s. 33–45, lipiec 2005. DOI: 10.1056/NEJMoa043800. PMID: 16000354.
Doubek M., Brychtova Y., Doubek R., Janku P., Mayer J. Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. „Annals of Hematology”. 83 (11), s. 726–7, listopad 2004. DOI: 10.1007/s00277-004-0904-5. PMID: 15278298.
Engel PJ., Johnson H., Baughman RP., Richards AI. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. „Annals of Internal Medicine”. 143 (4), s. 311–3, sierpień 2005. PMID: 16103481.
Dame C., Sutor AH. Primary and secondary thrombocytosis in childhood. „British Journal of Haematology”. 129 (2), s. 165–77, kwiecień 2005. DOI: 10.1111/j.1365-2141.2004.05329.x. PMID: 15813844.
Mitura-Lesiuk M., Filiks-Litwin B., Małek U., Kowalczyk JR. Diagnostic and therapeutic management of essential thrombocythemia in children. „Medycyna Wieku Rozwojowego”. 8 (3 Pt 2), s. 834–8, 2004. PMID: 15858255.
Scherer S., Ferrari R., Rister M. Treatment of essential thrombocythemia in childhood. „Pediatric Hematology and Oncology”. 20 (5), s. 361–5, 2003. PMID: 12775533.
Bieniaszewska M., Hellmann A., Kabata J., Rasze-Ja-Specht A. Essential thrombocythemia--clinical course from personal material. „Polskie Archiwum Medycyny Wewnętrznej”. 92 (2), s. 170–5, sierpień 1994. PMID: 7800586.
James CW. Anagrelide-induced cardiomyopathy. „Pharmacotherapy”. 20 (10), s. 1224–7, październik 2000. PMID: 11034048.
Raghavan M., Mazer MA., Brink DJ. Severe hypersensitivity pneumonitis associated with anagrelide. „The Annals of Pharmacotherapy”. 37 (9), s. 1228–31, wrzesień 2003. DOI: 10.1345/aph.1D071. PMID: 12921504.
Spencer EM., Lawrence DS. 'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide. „Clinical and Laboratory Haematology”. 28 (1), s. 63–5, luty 2006. DOI: 10.1111/j.1365-2257.2006.00740.x. PMID: 16430463.
Rappoport L., Körber A., Grabbe S., Dissemond J. Appearance of leg ulcers associated with intake of anagrelide. „Deutsche Medizinische Wochenschrift”. 132 (7), s. 319–21, luty 2007. DOI: 10.1055/s-2007-959325. PMID: 17286219.
Petrides PE., Gisslinger H., Steurer M., Linkesch W., Krumpl G., Schüller A., Widmann R. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. „Clinical Therapeutics”. 31 (2), s. 386–98, luty 2009. DOI: 10.1016/j.clinthera.2009.02.008. PMID: 19302911.
Solberg LA., Tefferi A., Oles KJ., Tarach JS., Petitt RM., Forstrom LA., Silverstein MN. The effects of anagrelide on human megakaryocytopoiesis. „British Journal of Haematology”. 99 (1), s. 174–80, październik 1997. PMID: 9359521.
Gillespie E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. „Biochemical Pharmacology”. 37 (14), s. 2866–8, lipiec 1988. PMID: 2456068.